CA2486833C - Solid dosage form comprising desmopressin and method for manufacturing thereof - Google Patents

Solid dosage form comprising desmopressin and method for manufacturing thereof Download PDF

Info

Publication number
CA2486833C
CA2486833C CA002486833A CA2486833A CA2486833C CA 2486833 C CA2486833 C CA 2486833C CA 002486833 A CA002486833 A CA 002486833A CA 2486833 A CA2486833 A CA 2486833A CA 2486833 C CA2486833 C CA 2486833C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
dosage form
solid dosage
granulate
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002486833A
Other languages
French (fr)
Other versions
CA2486833A1 (en
Inventor
Hakan Lomryd
Helena Nicklasson
Lars-Erik Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32981781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2486833(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Priority to CA002511353A priority Critical patent/CA2511353A1/en
Publication of CA2486833A1 publication Critical patent/CA2486833A1/en
Application granted granted Critical
Publication of CA2486833C publication Critical patent/CA2486833C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

The present invention relates to a novel pharmaceutical composition as a solid dosage farm comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a disaccharide, wherein the disaccharide has an average particle size in the range of from 70 to 500 µm. A method according to the present invention provides an improved production of solid dosage forms of desmopressin.

Description

SOLID DOSAGE FORM COMPRISING DESMOPRESSIN AND METHOD FOR
MANUFACTURING THEREOF
BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates to a novel pharmaceu-tical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof.
Description of the Related Art Desmopressin, also known as dDAVP, is the therapeu-tically active ingredient (as its acetate salt) in the pharmaceutical product Minirin~, which is marketed inter alia as a nasal spray and a tablet formulation.
Desmopressin is primarily used in the treatment of primary nocturnal enuresis, i.e. bedwetting, in children, but it is approved also for the treatment of nocturia and diabetes insipidus. The first market introduction of the tablet formulation was in Sweden in 1987.
In short, a solid dosage form such as a tablet formulation is typically manufactured by compression of a suitable granulate to the desired solid dosage form, where the granulate is composed of the required constituents as a mixture of solid particles. Typical such particles are the therapeutically active ingredient, various excipients (fillers), disintegrating agents, lubricants and binders, optionally together e.g. with flavoring agent, preservative and/or colorant. The commercially available Minirin~ tablet is prepared according to this general protocol, and the tablet was first disclosed as set forth in the patent US 5 047 398.
For a comprehensive overview of pharmaceutical tablet manufacturing, see "Tableting" (by N.A. Armstrong) in "Pharmaceutics - The science of dosage form design", pp 647-668; Ed. M.E. Aulton, Churchill Livingstone, Edinburgh, London, Melbourne and New York, 1988.
The Minirin~ tablet that is currently marketed, and thus produced in industrial scale, consists of the thera-peutically active ingredient desmopressin together with potato starch and lactose as excipients, and a suitable amount of binder and lubricant, respectively.
In any tablet compression of a granulate composed of a mixture of solid particles there is a general need to perform the compressing operation at the highest possible speed while at the same time minimising machine wear and obtaining tablets of a quality that meets the regulatory demands of all relevant territories.
SUMMARY OF THE INVENTION
It has now been discovered that a certain dimension of the excipient particles unexpectedly provides a substantial improvement on the speed of the manufacturing process, while both machine wear and tablet quality remain substantially unaltered compared to the industrial manufacturing process hitherto used. In essence, the dimension in question seems to affect the flowability of particles and granulate in such a manner that it provides an improved overall capacity, and hence speed, in the manufacturing process for the desmopressin tablet formulation.
More specifically, the present invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a disaccharide, wherein the said disaccharide has an average particle size in the range of from 70 to 500 Vim.
DETAILED DESCRIPTION OF EMBODIMENTS
In many cases the terms excipient, diluent and carrier can be used interchangeably, and they may even refer to one and the same substance, or to a mixture of similar such substances. The proper use and understanding of these terms is self-explanatory and lies well within the ability of a person skilled in the art of pharmaceutical formulation.
The pharmaceutical composition according to the present invention may optionally comprise at least one additive selected from a disintegrating agent, lubricant, binder, flavoring agent, preservative, colorant and a mixture thereof. Where considered suitable also other additives may be included. Representative examples of disintegrating agents, lubricants (e. g. magnesium stearate), binders (e. g. Kollidon~ 25, BASF), flavoring agents, preservatives and colorants, and suitable mixtures thereof, as well as any other conventional additive that may be considered by a person skilled in the art practising the present invention, can be found in "Handbook of Pharmaceutical Excipients"; Ed. A.H. Kibbe, 3rd Ed., American Pharmaceutical Association, USA and Pharmaceutical Press UK, 2000. As an example, also applicable in the practising of the present invention, it can be mentioned that typical amounts of lubricants and binders are in the order of less than 6 percent by weight of the pharmaceutical composition.
In the marketed tablet resulting from the hitherto used manufacturing process, the lactose particles (PharmatoseTM 150M provided by DMV, the Netherlands) have an average size of about 50 Vim, as determined by an air jet sieve (provided by Alpine GmbH, DE). That particle size does not provide a granulate that allows a compressing speed exceeding about 170 000 tablets per hour (h). In contrast thereto, the process according to the present invention allows a compressing speed of up to about 250 000 tablets/h with the desired tablet quality and retained low level of wear on the tabletting machinery.
In a preferred embodiment, said average particle size is in the range of from 75 to 350 Vim. In yet another preferred embodiment, said average particle size is in the range of from 100 to 200 Vim. In a further preferred embodiment, said average particle size is in the range of from 120 to 180 Vim. In the most preferred embodiment of the present invention, said average particle size is 140 ~m (as measured by an air jet sieve). The lactose particles sold as PharmatoseT"' DCL 15, marketed by DMV in the Netherlands, are of this most preferred average particle size. Other particular embodiments may involve use of e.g. PharmatoseT"" DCL 11, Pharmatose'"" DCL 21 and Pharmatose'~ DCL 40, all provided by the aforementioned DMV, which have an average particle size of 110, 150 and 165 ~,m, respectively.
According to the commercial provider the particle size distribution of PharmatoseT"" DCL 15 is that essentially all particles have a size below 500 ~.m, whereas approximately 72% of the particles have a size of from 75 to 350 Vim.
In an air jet sieve measurement of particle size, air is drawn upwards, through a sieve, from a rotating slit so that material on the sieve is fluidised. At the same time a negative pressure is applied to the bottom of the sieve which removes fine particles to a collecting device. Size analyses and determination of average particle size are performed by removal of particles from the fine end of the size distribution by using single sieves consecutively. See also "Particle Size Measurement", 5th Ed., p 178, vol. l; T. Allen, Chapman &
Hall, London, UK, 1997, for more details on this. For a person skilled in the art, the size measurement as such is thus of conventional character.
Accordingly, it is preferred that said disaccharide is lactose, more preferably lactose-a-monohydrate.
The total combined amount of said excipient, diluent and carrier is usually from 5 to 99, preferably from 50 to 99, percent by weight of the pharmaceutical composition, the balance up to 100% being the therapeutically active ingredient optionally together with the aforementioned additives, where the latter is preferably lubricant and binder.
The pharmaceutical composition as a solid dosage form according to the present invention is typically a 5 perorally available tablet. As an alternative non-limiting embodiment, the said tablet may be adapted for oral, including buccal and/or sublingual, administration.
The composition typically comprises desmopressin acetate in an amount of from 20 to 600 ~g per unit of solid dosage form. As an example, a typical tablet containing 100 ~g of desmopressin acetate is white, convex and oval (6.7 x 9.5 mm) with a thickness of 3-4 mm and a weight of 200 mg. As another example, a tablet containing 200 ~g of desmopressin acetate is white, round (8 mm diameter) and convex with a thickness of 3-4 mm and a weight of 200 mg.
Accordingly, a further aspect of the present invention relates to a method for the manufacturing of a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient, wherein said method comprises the steps of:
i) mixing desmopressin and an excipient, diluent or carrier, or mixture thereof, optionally in the presence of a wetting agent, wherein at least one of said excipient, diluent and carrier is a disaccharide, wherein said disaccharide has an average particle size in the range of from 70 to 500 Vim;
ii) subjecting the resulting mixture to formation of a granulate, optionally in the presence of a wetting agent, suitable for compression into said solid dosage form;
iii) optionally performing said mixing and/or forma tion of a granulate in the presence of at least one additive selected from a disintegrating agent, lubricant, binder, flavoring agent, pre-servative, colorant and a mixture thereof;
iv) optionally drying said granulate;
v) compressing said granulate into said solid dosage form.
The method according to the present invention can as such, once the specific components are identified and included, be practised by using conventional equipment for the manufacturing of pharmaceutical formulations. A
granulate suitable for compression into tablets typically has an average granulate size of at least about 100 Vim.
Discrete granules with a size above 2 mm are usually not transferred to the subsequent compressing step.
As non-limiting examples mention can be made of the following equipment for granulation: directly heated fluidised solid beds e.g. provided by GEA/Collette NV, BE
(UltimaProTM series), Huttlin GmbH, DE (HDG series), Diosna Dierks & Soehne GmbH, DE (VAC series), Fluid Air Inc., US (Magnaflo~ series) and Vector Corp., US (GMX
series); indirect conduction moving solids bed, including paddle systems, rotary systems and agitation systems, which are e.g. provided by Jaygo Inc., US (JRB and Novamix series), Paul 0. Abbe Inc., US (Rota-Cone, Rota-U, Rota Blade, Cylindrical Ribbon/Paddle, Plow and Sigma-blade series), Forberg A/S, NO (Forberg II series), Gemco Inc., US (D/3 Double Cone, v-Shape and Slant-Cone series), LittlefordDay Inc., US (Double Arm, Day Nauta and Daymax series), Patterson-Kelly, Harsco Corp., US (P-K Solids Processor~ series), Diosna as above (CCS and VAC
series), Romaco Zanchetta SpA, IT (Roto E, Roto D and Roto P series) and L.B. Bohle Maschinen and Verfahren GmbH, DE (Granumator GMA and Vagumator VMA series);
The aforementioned equipment in general also provides drying of the prepared granules.
In a preferred embodiment, said average particle size is in the range of from 75 to 350 Vim. In yet another preferred embodiment, said average particle size is in the range of from 100 to 200 Vim. In a further preferred embodiment, said average particle size is in the range of from 120 to 180 Vim. In the most preferred embodiment of the present invention, said average particle size is 140 Vim. The lactose particles sold as PharmatoseT"" DCL 15, marketed by DMV in the Netherlands, are of this most preferred average particle size. Other possible embodiments of the present method may involve the aforementioned variants of PharmatoseT"" DCL (vide supra).
It is accordingly preferred that said disaccharide is lactose, more preferably lactose-a,-monohydrate.
In the method according to the present invention, the manufactured solid dosage form is typically a perorally available tablet. Where desired, it may also be in a form and/or composition adapted for oromucosal administration. Preferred examples of the latter are buccal and/or sublingual administration. Examples of tablet compressing equipment suitable for the practising of the present invention are rotary presses provided by Elizabeth-Hata International, US (HT series), Courtoy NV, BE (R090F, R100M, R190FT, R290FT, R292F and 8233 series), Vector Corp., US (2000, 200 and Magna series), Fette GmbH, DE (Hightech, Medium, Special and WIP series), Manesty, UK (Xpress, Diamond and Value series) and Kilian & Co. GmbH, DE (S, T, E, RX and KTS series).
In a preferred embodiment of the present inventive method said steps of mixing and formation of granulate are performed in a single integrated machinery that is adapted for such a "one-pot", i.e. combined, process. An example of such integrated machinery, alternatively denoted one-pot (single pot) equipment, is the FT series, provided by Forberg A/S, Norway.
It is preferred that where used, said wetting agent is selected from water and a mixture of water and an alcohol, preferably ethanol. A water/ethanol 1:3 mixture is typically used, albeit many other combinations are also possible.
As indicated above, it is preferred that said resulting mixture is subjected to formation of a granulate with an average granulate size of a least 100 Vim, preferably in the range of from 100 ~m to 2 mm.
The method is performed in such a manner that the total combined amount of said excipient, diluent and carrier is from 5 to 99, preferably from 50 to 99, percent by weight of the pharmaceutical composition.
In the most preferred embodiment, desmopressin acetate is used and mixed with said excipient, diluent and/or carrier in an amount that eventually provides from to 600 ~g of desmopressin acetate per unit of solid dosage form (see above and the experimental part for examples of a tablet).
15 In order to substantiate and illustrate the present invention in more detail, the following example is provided. It shall not be construed as a limitation of how the invention may be practised.
Example 20 Example 1: Preparation of solid dosage form of dDAVP
Desmopressin acetate (100 or 200 g; provided by PolyPeptide Laboratories AB, SE), polyvinyl pyrrolidone (PVP) as binder (1,84 kg; Kollidon~ 25 provided by BASF
GmbH, DE) and granulation liquid (water/ethanol 1:3 mixture) are combined in a vessel and mixed at room temperature until a clear solution is achieved. The potato starch (77 kg, average particle size about 40-50 ~m according to laser diffraction measurements;
AmylSolVat provided by Lyckeby Starkelse AB, SE), is weighed and sieved through a 2 mm sieve. Lactose (120 kg, DCL 15 provided by DMV NV, NL; see above for the details of this product) is weighed and loaded together with the starch into a single pot mixer (FT-350; provided by Forberg A/S, NO) and mixed therein. The granulation liquid solution is then sprayed onto the powder mixture, after which the moist granulate is dried with warm air (50°C), all with continued mixing. The dried granulate is then sieved (2 mm) and transferred to a double cone mixer. Magnesium stearate (max 1.0 kg; provided by Peter Greven NV, NL) is then weighed in, sieved (1 mm) and transferred to the double cone mixer for final mixing.
Tablets are then compressed from the resulting mixture by using a conventional rotary tablet compression machine (Kilian S-250), whereby a compressing speed of about 250 000 tablets/h is attainable with adequate tablet quality and low machine wear. A tablet of adequate quality has a smooth surface without scratches or chipped edges, and it shows no tendencies to lamination (so-called capping).
The process is typically adapted to provide a tablet containing 100 or 200 ~g of desmopressin acetate with the aforementioned appearance, dimension and weight.

Claims (29)

1. A pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a disaccharide, wherein said disaccharide has an average particle size in the range of from 70 to 500 µm.
2. The pharmaceutical composition according to claim 1, wherein said average particle size is in the range of from 75 to 350 µm.
3. The pharmaceutical composition according to claim 2, wherein said average particle size is in the range of from 100 to 200 µm.
4. The pharmaceutical composition according to claim 3, wherein said average particle size is in the range of from 120 to 180 µm.
5. The pharmaceutical composition according to any of claims 1 to 4, wherein said disaccharide is lactose.
6. The pharmaceutical composition according to any one of claims 1 to 4, wherein said disaccharide is lactose-.alpha.-monohydrate.
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the total combined amount of said excipient, diluent and carrier comprises from 5 to 99 percent by weight of the pharmaceutical composition.
8. The pharmaceutical composition according to claim 7, wherein the total combined amount of said excipient, diluent and carrier comprises from 50 to 99 percent by weight of the pharmaceutical composition.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein said solid dosage form is a perorally available tablet.
10. The pharmaceutical composition according to claim 9, wherein said dosage form is a perorally available tablet adapted for oromucosal administration.
11 11. The pharmaceutical composition according to claim 10, wherein said solid dosage form is a perorally available tablet that is adapted for at least one of buccal and sublingual administration.
12. The pharmaceutical composition according to any one of claims 1 to 11, which comprises desmopressin acetate in an amount of from 20 to 600 µg per unit of solid dosage form.
13. A method for the manufacture of a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient, wherein said method comprises the steps of:
i) mixing desmopressin and an excipient, diluent or carrier, or mixture thereof, optionally in the presence of a wetting agent, wherein at least one of said excipient, diluent and carrier is a disaccharide, wherein said disaccharide has an average particle size in the range of from 70 to 500 µm;
ii) subjecting the resulting mixture to formation of a granulate, optionally in the presence of a wetting agent, for compression into said solid dosage form;
iii) optionally performing at least one of said mixing and formation of a granulate in the presence of at least one additive selected from the group consisting of a disintegrating agent, lubricant, binder, flavouring agent, preservative, colorant and a mixture thereof;
iv) optionally drying said granulate;
v) compressing said granulate into said solid dosage form.
14. The method according to claim 13, wherein said average particle size is in the range of from 75 to 350 µm.
15. The method according to claim 14, wherein said average particle size is in the range of from 100 to 200 µm.
16. The method according to claim 15, wherein said average particle size is in the range of from 120 to 180 µm.
17. The method according to any one of claims 13 to 16, wherein said disaccharide comprises lactose.
18. The method according to any one of claims 13 to 16, wherein said disaccharide comprises lactose-.alpha.-monohydrate.
19. The method according to any one of claims 13 to 18, wherein said solid dosage form is a perorally available tablet.
20. The method according to claim 19, wherein said solid dosage form is a perorally available tablet that is adapted for oromucosal administration.
21. The method according to claim 20, wherein said solid dosage form is a perorally available tablet that is adapted for at least one of buccal and sublingual administration.
22. The method according to any one of claims 13 to 21, wherein said steps of mixing and formation of a granulate are performed in a single integrated machinery that is adapted for such a combined process.
23. The method according to any one of claims 13 to 22, wherein said wetting agent is selected from water, and a mixture of water and an alcohol.
24. The method according to claim 23, wherein said wetting agent is selected from water, and a mixture of water and ethanol.
25. The method according to any one of claims 13 to 24, wherein said resulting mixture is subjected to formation of a granulate with an average granulate size of at least 100 µm.
26. The method according to claim 25, wherein said resulting mixture is subjected to formation of a granulate with an average granulate size from 100 µm to 2 mm.
27. The method according to any one of claims 13-26, wherein the total combined amount of said excipient, diluent and carrier comprises from 5 to 99 percent by weight of the pharmaceutical composition.
28. The method according to claim 27, wherein the total combined amount of said excipient, diluent and carrier comprises from 50 to 99 percent by weight of the pharmaceutical composition.
29. The method according to any one of claims 13 to 28, wherein desmopressin acetate is used and mixed with the excipient, diluent or carrier in an amount that provides from 20 to 600 µg of desmopressin acetate per unit of solid dosage form.
CA002486833A 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin and method for manufacturing thereof Expired - Lifetime CA2486833C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002511353A CA2511353A1 (en) 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin and method for manufacturing thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03009659A EP1473029B1 (en) 2003-04-30 2003-04-30 Solid dosage form comprising desmopressin
EP03009659.8 2003-04-30
PCT/EP2004/004597 WO2004096181A2 (en) 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002511353A Division CA2511353A1 (en) 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin and method for manufacturing thereof

Publications (2)

Publication Number Publication Date
CA2486833A1 CA2486833A1 (en) 2004-11-11
CA2486833C true CA2486833C (en) 2005-08-02

Family

ID=32981781

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002486833A Expired - Lifetime CA2486833C (en) 2003-04-30 2004-04-30 Solid dosage form comprising desmopressin and method for manufacturing thereof

Country Status (18)

Country Link
EP (2) EP1473029B1 (en)
JP (1) JP4597124B2 (en)
KR (1) KR100766455B1 (en)
CN (1) CN100438857C (en)
AT (1) ATE291419T1 (en)
AU (1) AU2004233596B2 (en)
CA (1) CA2486833C (en)
DE (1) DE60300414T2 (en)
DK (1) DK1473029T3 (en)
ES (1) ES2236640T3 (en)
MX (1) MXPA05011591A (en)
NO (1) NO331205B1 (en)
NZ (1) NZ542653A (en)
PL (1) PL211799B1 (en)
PT (1) PT1473029E (en)
RU (1) RU2290945C2 (en)
SI (1) SI1473029T1 (en)
WO (1) WO2004096181A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ATE301990T1 (en) * 2003-07-25 2005-09-15 Ferring Bv PHARMACEUTICAL DESMOPRESSIN PREPARATION AS A SOLID DOSAGE FORM AND METHOD FOR THEIR PRODUCTION
CA2490601C (en) * 2003-12-29 2006-05-02 Ferring B.V. Method for preparing solid dosage form of desmopressin
ES2319054B1 (en) 2007-08-06 2010-02-12 Gp Pharm S.A. ORAL PHARMACEUTICAL COMPOSITION OF DESMOPRESINA.
CN102423485B (en) * 2011-12-08 2014-08-06 赵联华 Oral composition containing desmopressin acetate and preparation method for oral composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8306367L (en) * 1983-11-18 1985-05-19 Ferring Ab ANTIDIURETICALLY EFFECTIVE PHARMACEUTICAL PREPARATION
SE9400918L (en) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabilized composition for oral administration of peptides
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
JP2001139461A (en) * 1999-11-10 2001-05-22 Ohta Pharmaceut Co Ltd Quickly collapsable tablet
JP4596586B2 (en) * 2000-01-27 2010-12-08 旭化成ケミカルズ株式会社 Trehalose particles
PL361452A1 (en) * 2001-07-27 2004-10-04 Yamanouchi Pharmaceutical Co.Ltd. Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same

Also Published As

Publication number Publication date
CA2486833A1 (en) 2004-11-11
AU2004233596A1 (en) 2004-11-11
RU2005131494A (en) 2006-03-20
JP2006524663A (en) 2006-11-02
NO20055016L (en) 2005-10-27
EP1473029B1 (en) 2005-03-23
JP4597124B2 (en) 2010-12-15
EP1670439A2 (en) 2006-06-21
KR20060012592A (en) 2006-02-08
RU2290945C2 (en) 2007-01-10
CN100438857C (en) 2008-12-03
NO331205B1 (en) 2011-10-31
CN1780608A (en) 2006-05-31
NZ542653A (en) 2008-04-30
PL211799B1 (en) 2012-06-29
DE60300414T2 (en) 2006-05-11
SI1473029T1 (en) 2005-10-31
KR100766455B1 (en) 2007-10-15
PT1473029E (en) 2005-05-31
AU2004233596B2 (en) 2010-04-08
DK1473029T3 (en) 2005-04-18
MXPA05011591A (en) 2005-12-15
ATE291419T1 (en) 2005-04-15
WO2004096181A3 (en) 2004-12-23
EP1473029A1 (en) 2004-11-03
ES2236640T3 (en) 2005-07-16
PL379703A1 (en) 2006-11-13
WO2004096181A2 (en) 2004-11-11
DE60300414D1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
US20080014265A1 (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
US20110033535A1 (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
US7022340B2 (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EP1829532A1 (en) Stable solid dosage form comprising desmopressin
CA2486833C (en) Solid dosage form comprising desmopressin and method for manufacturing thereof
US7018653B2 (en) Method for preparing solid dosage form of desmopressin
EP1550439B1 (en) Method for preparing a solid dosage form of desmopressin
CA2511353A1 (en) Solid dosage form comprising desmopressin and method for manufacturing thereof
WO2007098945A2 (en) Stable solid dosage form comprising desmopressin
IL167612A (en) Method for manufacturing a pharmaceutical composition as solid dosage form comprising desmopressin acetate as a therapeutically active agent
RU2334505C2 (en) Method of preparation of hard medicinal form of desmopressin

Legal Events

Date Code Title Description
EEER Examination request